Stifel Nicolaus Reiterates Buy Rating for Krystal Biotech (NASDAQ:KRYS)

Krystal Biotech (NASDAQ:KRYS)‘s stock had its “buy” rating reiterated by research analysts at Stifel Nicolaus in a research note issued on Tuesday, Benzinga reports. They presently have a $204.00 target price on the stock, up from their prior target price of $178.00. Stifel Nicolaus’ price target suggests a potential upside of 20.25% from the company’s current price.

Other analysts have also recently issued research reports about the stock. Citigroup raised their target price on shares of Krystal Biotech from $160.00 to $195.00 and gave the company a “buy” rating in a report on Tuesday, February 27th. William Blair reissued an “outperform” rating on shares of Krystal Biotech in a report on Tuesday, February 27th. Finally, Guggenheim raised their price objective on shares of Krystal Biotech from $130.00 to $175.00 and gave the stock a “buy” rating in a report on Tuesday, February 27th. Nine equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Krystal Biotech has a consensus rating of “Buy” and a consensus target price of $164.22.

Krystal Biotech Stock Performance

NASDAQ KRYS opened at $169.64 on Tuesday. The firm has a 50 day simple moving average of $157.74 and a 200-day simple moving average of $129.49. Krystal Biotech has a one year low of $82.09 and a one year high of $189.97. The firm has a market cap of $4.84 billion, a price-to-earnings ratio of 2,120.77 and a beta of 0.85.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings data on Monday, February 26th. The company reported $0.30 EPS for the quarter, beating the consensus estimate of ($0.52) by $0.82. The business had revenue of $42.14 million during the quarter, compared to analysts’ expectations of $27.43 million. During the same period in the previous year, the business posted ($1.25) EPS. Equities analysts predict that Krystal Biotech will post 1.61 EPS for the current fiscal year.

Insider Activity at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction on Monday, March 11th. The stock was sold at an average price of $170.96, for a total transaction of $4,274,000.00. Following the completion of the transaction, the insider now directly owns 1,550,882 shares of the company’s stock, valued at $265,138,786.72. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In related news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction on Monday, March 11th. The stock was sold at an average price of $170.96, for a total transaction of $4,274,000.00. Following the completion of the transaction, the insider now directly owns 1,550,882 shares of the company’s stock, valued at $265,138,786.72. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CAO Kathryn Romano sold 8,087 shares of Krystal Biotech stock in a transaction on Monday, February 26th. The stock was sold at an average price of $136.91, for a total value of $1,107,191.17. Following the transaction, the chief accounting officer now directly owns 12,556 shares of the company’s stock, valued at $1,719,041.96. The disclosure for this sale can be found here. Insiders sold 40,587 shares of company stock valued at $6,535,591 in the last ninety days. Corporate insiders own 14.10% of the company’s stock.

Hedge Funds Weigh In On Krystal Biotech

Institutional investors have recently made changes to their positions in the stock. TimesSquare Capital Management LLC acquired a new position in shares of Krystal Biotech in the third quarter worth $14,272,000. Charles Schwab Investment Management Inc. raised its holdings in shares of Krystal Biotech by 10.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 179,780 shares of the company’s stock worth $20,854,000 after acquiring an additional 17,614 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Krystal Biotech by 40.7% in the third quarter. Vanguard Group Inc. now owns 2,400,142 shares of the company’s stock worth $278,416,000 after acquiring an additional 693,852 shares during the last quarter. Trexquant Investment LP raised its holdings in shares of Krystal Biotech by 8.8% in the third quarter. Trexquant Investment LP now owns 8,113 shares of the company’s stock worth $941,000 after acquiring an additional 657 shares during the last quarter. Finally, Northern Trust Corp raised its holdings in shares of Krystal Biotech by 2.0% in the third quarter. Northern Trust Corp now owns 213,263 shares of the company’s stock worth $24,739,000 after acquiring an additional 4,129 shares during the last quarter. 86.29% of the stock is owned by institutional investors and hedge funds.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).